var data={"title":"Lamivudine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Lamivudine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6432?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=lamivudine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Lamivudine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=lamivudine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Lamivudine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709005\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Lactic acidosis and severe hepatomegaly with steatosis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs and other antiretrovirals. Discontinue lamivudine if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Exacerbations of hepatitis B:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued anti-hepatitis B therapy (including lamivudine-HBV) or are coinfected with hepatitis B virus (HBV) and HIV and have discontinued lamivudine. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti-hepatitis B therapy or who discontinue lamivudine and are coinfected with HIV-1 and HBV. If appropriate, initiation of anti-hepatitis B therapy may be warranted.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Important differences among lamivudine-containing products:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Lamivudine tablets and oral solution (used to treat HIV-1 infection) contain a higher dose of lamivudine than lamivudine-HBV tablets and oral solution (used to treat chronic hepatitis B infection). Patients with HIV-1 infection should receive only dosage forms appropriate for treatment of HIV-1.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risk of HIV-1 resistance if lamivudine-HBV is used in patients with unrecognized or untreated HIV-1:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Lamivudine-HBV is not approved for the treatment of HIV-1 infection because the lamivudine dosage in lamivudine-HBV is subtherapeutic and monotherapy is inappropriate for the treatment of HIV-1 infection. HIV-1 resistance may emerge in chronic hepatitis B-infected patients with unrecognized or untreated HIV-1 infection. HIV counseling and testing should be offered to all patients before beginning treatment with lamivudine-HBV and periodically during treatment.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186636\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Epivir;</li>\n      <li>Epivir HBV</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186637\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>3TC;</li>\n      <li>Heptovir</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186676\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antihepadnaviral, Reverse Transcriptase Inhibitor, Nucleoside (Anti-HBV);</li>\n      <li>\n        Antiretroviral, Reverse Transcriptase Inhibitor, Nucleoside (Anti-HIV)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186641\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> The formulation and dosage of Epivir HBV are not appropriate for patients infected with both HBV and HIV; tenofovir and lamivudine are a preferred nucleoside reverse transcriptase inhibitor (NRTI) backbone in a fully suppressive antiretroviral regimen and for the treatment of HBV coinfection (HHS [adult] 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HIV-1 infection (Epivir, 3TC [Canadian product]):</b> Oral (use in combination with other antiretroviral agents): 150 mg twice daily or 300 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Lamivudine is a component of recommended initial regimens for any ART-naive patient (when coadministered with tenofovir plus dolutegravir or with tenofovir plus raltegravir) or for ART-naive patients who are HLA-B*5701 negative (when coadministered with abacavir plus dolutegravir) (HHS [adult] 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HIV-1 nonoccupational postexposure prophylaxis (nPEP) (Epivir) (off-label use) (</b>\n      <b>HHS [nPEP] 2016)</b>: Oral: <b>Note:</b> Initiate therapy within 72 hours of exposure and continue for 28 days; use in combination with other antiretroviral agents.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;60 mL/minute: Lamivudine is not a component of the recommended antiretroviral regimens for these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;60 mL/minute: Dose should be adjusted based on renal function.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Treatment of hepatitis B (Epivir HBV, Heptovir [Canadian product]):</b> Oral: 100 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment duration (AASLD practice guidelines):</i> Treatment duration for nucleos(t)ide analog-based therapy (eg, lamivudine) is variable and influenced by HBeAg status, duration of HBV suppression, and presence of cirrhosis/decompensation (AASLD [Terrault 2016):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients <i>without</i> cirrhosis:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hepatitis B e antigen (HBeAg) positive immune-active chronic hepatitis: Treat until HBeAg seroconversion; after seroconversion, prolonged duration of therapy is often required in patients treated with nucleos(t)ide analogues. Optimal duration is unknown; however, consolidation therapy is generally a minimum of 12 months of persistently normal ALT and undetectable serum HBV DNA levels after HBeAg seroconversion</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">HBeAg-negative immune-active chronic hepatitis: Indefinite antiviral therapy is suggested unless there is competing rationale for discontinuation (risk/benefit decision); treatment discontinuation may be considered in patients with loss of HBsAg; however, there is insufficient evidence to guide decisions in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients <i>with </i>cirrhosis:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">HBeAg-positive immune-active chronic hepatitis: In patients who seroconvert on therapy, continue antiviral therapy indefinitely due to concerns with decompensation and death, unless there is a strong competing rationale for discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">HBeAg-negative immune-active chronic hepatitis: Treatment discontinuation is not recommended due to potential for decompensation and death (limited data).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Viral breakthrough (</i>\n      <i>AASLD practice guidelines)</i>\n      <i>:</i> Patients with confirmed viral breakthrough (HBV DNA &ge;100 units/mL with previously undetectable levels [&lt;10 units/mL] or &gt;1 log increase in HBV DNA) should either be switched to an alternative antiviral monotherapy agent with a high genetic barrier to resistance <b>or</b> receive a second antiviral agent with a complementary resistance profile; consult current clinical practice guidelines for recommended agents (AASLD [Terrault 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Treatment of hepatitis B/HIV coinfection (in patients with both infections requiring treatment) (Epivir): Note:</b> The formulation and dosage of Epivir HBV are not appropriate for patients infected with both HBV and HIV. Tenofovir and lamivudine are a preferred NRTI backbone in a fully suppressive antiretroviral regimen for the treatment of HIV/HBV coinfection (HHS [adult] 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 150 mg twice daily or 300 mg once daily, in combination with other antiretrovirals in an antiretroviral (ARV) regimen (HHS [adult] 2017)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186659\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=lamivudine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Lamivudine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HIV-1 infection, treatment: Note:</b> Use in combination with other antiretroviral agents.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants 1 to 3 months (off-label dose): Epivir: Oral solution (10 mg/mL): 4 mg/kg/dose twice daily (HHS [pediatric] 2017; Tremoulet 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &ge;3 months of age, Children, and Adolescents: <b>Note:</b> Once-daily dosing is <b>not </b>recommended as initial therapy, especially with use of the oral solution in infants and young children. Efficacy of once-daily dosing has only been demonstrated in patients who transitioned from twice-daily dosing after 36 weeks of treatment. Some experts recommend reserving once-daily therapy for use as a component of a once-daily regimen in clinically stable patients &ge;3 years of age who have undetectable viral loads and stable CD4 counts (HHS [pediatric] 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral solution:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Epivir (10 mg/mL): 10 mg/kg/day in 1 to 2 divided doses (maximum: 300 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">3TC [Canadian product]:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&lt;25 kg: 8 mg/kg/day in 1 to 2 divided doses (maximum: 300 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ge;25 kg: 150 mg twice daily or 300 mg once daily (maximum: 300 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Alternate recommendations: 8 to 10 mg/kg/dose once daily; maximum dose: 300 mg/dose (HHS [pediatric] 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral tablets: Epivir, 3TC [Canadian product]: Weight-band dosing for patients weighing &ge;14 kg who are able to swallow tablets (using scored 150 mg tablets):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">14 to &lt;20 kg: 75 mg twice daily or 150 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;20 to &lt;25 kg: 75 mg in the morning, 150 mg in the evening or 225 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;25 kg: 150 mg twice daily or 300 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HIV-1 nonoccupational postexposure prophylaxis (nPEP) (off-label use) (</b>\n      <b>HHS [nPEP] 2016):</b> <b>Note:</b> Initiate therapy within 72 hours of exposure and continue for 28 days in combination with other antiretroviral agents; Oral: Epivir:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents &lt;16 years of age:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weight-directed dosing: Oral solution (10 mg/mL): 4 mg/kg/dose twice daily (maximum: 150 mg/dose)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weight-band dosing: Oral tablet: For patients &ge;14 kg who are able to swallow tablets (scored 150 mg tablets):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">14 to &lt;20 kg: 75 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">20 to &lt;25 kg: 75 mg in the morning and 150 mg in the evening</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;25 kg: 150 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents &ge;16 years of age: Oral solution (10 mg/mL) or oral tablet:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;50 kg: 4 mg/kg twice daily (maximum: 150 mg/dose)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;50 kg: 150 mg twice daily <b>or </b>300 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Prevention of perinatal HIV transmission (off-label use; HHS [perinatal] 2017): Note:</b> To be used as part of a 3-drug empiric therapy regimen with zidovudine and nevirapine in infants at higher risk of HIV acquisition. Initiate therapy as soon as possible after birth, preferably within 6 to 12 hours of delivery. The optimal duration for empiric therapy in infants at higher risk of perinatal HIV transmission is not known. Some experts continue the 3-drug combination for 6 weeks; others discontinue the lamivudine and nevirapine components after the return of a negative newborn test. If empiric therapy is started in breastfeeding infants of mothers initially diagnosed with acute HIV infection postpartum (breastfeeding started prior to diagnosis of maternal HIV and infant&rsquo;s initial HIV test is negative), duration of treatment is not known, but a 28-day course may be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;32 weeks&rsquo; gestation at birth:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Birth to 4 weeks: Oral: Epivir: 2 mg/kg/dose twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">4 weeks to 6 weeks: Oral: Epivir: 4 mg/kg/dose twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Treatment of hepatitis B/HIV coinfection (in patients with both infections requiring treatment): </b> <b>Note:</b> The formulation and dosage of Epivir HBV are not appropriate for patients infected with both HBV and HIV.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children: Oral: Epivir: 4 mg/kg/dose (maximum: 150 mg) twice daily, in combination with other antiretrovirals in an ARV regimen (HHS [pediatric] 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Treatment of hepatitis B:</b> <b>Note:</b> Tablets and oral solution may be used interchangeably; for doses &lt;100 mg, oral solution is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Epivir HBV: Children and Adolescents 2 to 17 years: Oral: 3 mg/kg/dose once daily (maximum: 100 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Heptovir [Canadian product]: Adolescents &ge;16 years of age: Refer to adult dosing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186642\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186643\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HIV-1 infection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ESRD requiring hemodialysis: Administer 50 mg first dose, then 25 mg once daily (IDSA [Lucas 2014]). Negligible amounts are removed by 4-hour hemodialysis or peritoneal dialysis. Supplemental dosing not needed; however, dosing after dialysis is recommended (HHS [adult] 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents &ge;25 kg and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;50 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 30 to 49 mL/minute: Administer 150 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 15 to 29 mL/minute: Administer 150 mg first dose, then 100 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 5 to 14 mL/minute: Administer 150 mg first dose, then 50 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;5 mL/minute: Administer 50 mg first dose, then 25 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &ge;3 months of age, Children, and Adolescents &lt;25 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Epivir: There are no dosage adjustments provided in the manufacturer's labeling (insufficient data); however, dose reduction should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">3TC [Canadian product]:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 30 to 50 mL/minute: Administer 4 mg/kg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 15 to 29 mL/minute: Administer 4 mg/kg first dose, then 2.6 mg/kg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 5 to 14 mL/minute: Administer 4 mg/kg first dose, then 1.3 mg/kg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;5 mL/minute: Administer 1.3 mg/kg first dose, then 0.7 mg/kg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Treatment of hepatitis B patients:</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;50 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 30 to 49 mL/minute: Administer 100 mg first dose, then 50 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 15 to 29 mL/minute: Administer 100 mg first dose, then 25 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 5 to 14 mL/minute: Administer 35 mg first dose, then 15 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;5 mL/minute: Administer 35 mg first dose, then 10 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ESRD requiring hemodialysis: Negligible amounts are removed by 4-hour hemodialysis or peritoneal dialysis. Supplemental dosing not needed; however, dosing after dialysis is recommended (HHS [adult] 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16160258\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary. However, has not been studied in the setting of decompensated liver disease. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186610\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Epivir: 10 mg/mL (240 mL) [contains methylparaben, propylene glycol, propylparaben; strawberry-banana flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Epivir HBV: 5 mg/mL (240 mL) [contains methylparaben, propylene glycol, propylparaben; strawberry-banana flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/mL (240 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Epivir: 150 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Epivir: 300 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Epivir HBV: 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg, 150 mg, 300 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186595\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46041979\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">3TC: 10 mg/mL (240 mL) [contains methylparaben, propylene glycol, propylparaben; strawberry-banana flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Heptovir: 5 mg/mL (240 mL) [contains methylparaben, propylene glycol, propylparaben; strawberry-banana flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">3TC: 150 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">3TC: 300 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Heptovir: 100 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186613\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: May be administered without regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186611\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic hepatitis B (Epivir HBV):</b> Treatment of chronic hepatitis B associated with evidence of hepatitis B viral replication and active liver inflammation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Use only when an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate. Lamivudine-HBV has not been evaluated in patients coinfected with HIV, hepatitis C virus, or hepatitis delta virus; with decompensated liver disease; or in liver transplant recipients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HIV-1 infection (Epivir):</b> Treatment of HIV-1 in combination with other antiretroviral agents</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25726720\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>HIV-1 nonoccupational postexposure prophylaxis; Prevention of perinatal HIV transmission</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186683\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LamiVUDine may be confused with lamoTRIgine </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Epivir may be confused with Combivir</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186602\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Incidence data include patients on combination therapy with other antiretroviral agents.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (21% to 35%), fatigue (24% to 27%), neuropathy (12%), insomnia (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (15% to 33%), diarrhea (14% to 18%), pancreatitis (&le;18%; higher percentage in pediatric patients), abdominal pain (9% to 16%), vomiting (13% to 15%), sore throat (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Neutropenia (7% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum transaminases (2% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (25%; includes ear, nose, and throat)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Myalgia (8% to 14%), musculoskeletal pain (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasal signs and symptoms (20%), cough (18%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (10%), depression (9%), chills (7% to 10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (5% to 9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Anorexia (10%), increased serum lipase (10%), abdominal cramps (6%), dyspepsia (5%), increased amylase (&le;4%), heartburn</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Thrombocytopenia (1% to 4%), hemoglobinemia (2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Increased creatine phosphokinase (9%), arthralgia (5% to 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (7% to 10%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Alopecia, anaphylaxis, anemia, exacerbation of hepatitis B, hepatomegaly, hyperbilirubinemia, hyperglycemia, immune reconstitution syndrome, lactic acidosis, liver steatosis, lymphadenopathy, myasthenia, paresthesia, peripheral neuropathy, pruritus, pure red cell aplasia, redistribution of body fat, rhabdomyolysis, splenomegaly, stomatitis, urticaria, weakness, wheezing </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186616\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to lamivudine or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186599\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fat redistribution: May cause redistribution/accumulation of fat (eg, central obesity, buffalo hump, peripheral wasting, facial wasting, breast enlargement, cushingoid appearance).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves disease, polymyositis, Guillain-Barr&eacute; syndrome) later in therapy; further evaluation and treatment may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lactic acidosis/hepatomegaly: <b>[US Boxed Warning]: Lactic acidosis and severe hepatomegaly with steatosis have been reported with nucleoside analogues, including fatal cases; suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity;</b> use with caution in patients with risk factors for liver disease (risk may be increased with female gender, obesity, pregnancy, or prolonged exposure); transaminase elevation may/may not accompany hepatomegaly and steatosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pancreatitis: Has been reported, particularly in HIV-infected children with a history of nucleoside use. Discontinue treatment if signs of symptoms of pancreatitis occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chronic hepatitis B: <b>[US Boxed Warning]: </b><b>Severe acute exacerbations of hepatitis B (some fatal) have been reported in patients with HBV or HIB/HBV coinfection who have discontinued lamivudine; hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months after discontinuation. <b>Initiate antihepatitis B (HBV) medications if clinically appropriate.</b></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage reduction recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Resistance:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- HIV: <b>[US Boxed Warning]: HIV-1 resistance may emerge in chronic hepatitis B-infection patients with unrecognized or untreated HIV-1 infection. Counseling and HIV testing should be offered to all patients before beginning treatment with lamivudine for hepatitis B and then periodically during treatment. Lamivudine dosing for hepatitis B is subtherapeutic if used for HIV-1 infection treatment. Lamivudine monotherapy is not appropriate for HIV-1 infection treatment.</b> Lamivudine resistant HIV-1 can develop rapidly and limit treatment options if used in unrecognized or untreated HIV-1 infection or if a patient becomes coinfected during HBV treatment. Lamivudine dosing for hepatitis B is also subtherapeutic if used for HIV-1/HBV coinfection treatment. If lamivudine is chosen as part of a HIV-1 treatment regimen in coinfected patients, the higher lamivudine dosage indicated for HIV-1 therapy should be used, with other drugs, in an appropriate combination regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- HBV: Patients treated with lamivudine-HBV with YMDD-mutant HBV showed diminished treatment response (lower rates of HbeAg seroconversion and HbeAg loss, more frequent return of positive HBV DNA, more frequent ALT elevations) compared to patients without evidence of YMDD substitutions. Emergence of lamivudine resistant HBV variants has also been reported in HIV-1/HBV coinfected patients who have received lamivudine-containing antiretroviral regimens.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Interferon alfa: Use with caution in combination with interferon alfa with or without ribavirin in HIV/HCV coinfected patients; monitor closely for hepatic decompensation, anemia, or neutropenia; dose reduction or discontinuation of interferon and/or ribavirin may be required if toxicity evident.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Use with caution in pediatric patients with a history of prior antiretroviral nucleoside exposure or pancreatitis, or other significant risk factors for development of pancreatitis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate product selection: Epivir HBV: <b>[US Boxed Warning]: Do not use Epivir HBV tablets or Epivir HBV oral solution for the treatment of HIV. </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral solution: Use of lamivudine oral solution has been associated with lower rates of virologic suppression, lower plasma lamivudine exposure, and increased rates of resistance when compared to lamivudine tablets in pediatric clinical trials. Lamivudine scored tablet is the preferred formulation for HIV-1 infected pediatric patients weighing &ge;14 kg and for whom a solid dosage form is appropriate; consider more frequent monitoring of HIV-1 viral load if oral solution is used.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sucrose: Lamivudine oral solutions contains 3 g of sucrose/15 mL; advise diabetic patients of sucrose content.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Zar 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">-HIV: Do not use as monotherapy in treatment of HIV. Treatment of HIV in patients with unrecognized/untreated HBV may lead to rapid HBV resistance; HIV-infected patients should be screened for hepatitis B prior to starting lamivudine HIV therapy. Lamivudine combined with emtricitabine is not recommended as a dual-nucleoside reverse transcriptase inhibitor (NRTI) combination due to similar resistance patterns and negligible additive antiviral activity. Do not use lamivudine/abacavir (plus efavirenz or plus atazanavir/ritonavir) in adolescent and adult HIV-1 patients with a pre-ART HIV RNA &gt;100,000 copies/mL (HHS [adult] 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- HBV: Current clinical hepatitis B practice guidelines do not recommend lamivudine for initial use in the management of chronic HBV due to low barrier to resistance; other antiviral agents with a high genetic barrier to drug resistance are preferred (eg, tenofovir or entecavir) (AASLD [Terrault 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- HIV/HBV coinfection: Lamivudine and tenofovir is a recommended NRTI backbone in a fully suppressive antiretroviral regimen to provide activity against both HIV and HBV (HHS [adult] 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299572\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> MRP2</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186604\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9544&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Cabozantinib: MRP2 Inhibitors may increase the serum concentration of Cabozantinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Emtricitabine: LamiVUDine may enhance the adverse/toxic effect of Emtricitabine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Antiretroviral Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sorbitol: May decrease the serum concentration of LamiVUDine. Management: When possible, avoid chronic coadministration of sorbitol-containing solutions with lamivudine, but if this combination cannot be avoided, monitor patients more closely for possible therapeutic failure associated with decreased lamivudine exposure.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimethoprim: May increase the serum concentration of LamiVUDine.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186632\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food decreases the rate of absorption and C<sub>max</sub>; however, there is no change in the systemic AUC. Management: Administer with or without food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186620\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Lamivudine has a high level of transfer across the human placenta. No increased risk of overall birth defects has been observed following first trimester exposure according to data collected by the antiretroviral pregnancy registry. Maternal antiretroviral therapy (ART) may increase the risk of preterm delivery, although available information is conflicting possibly due to variability of maternal factors (disease severity; gestational age at initiation of therapy); however, maternal antiretroviral medication should not be withheld due to concerns of preterm birth. Based on data collected by the antiretroviral pregnancy registry, the risk of spontaneous abortions, induced abortions, and preterm birth is less in lamivudine-containing regimens compared with regimens without lamivudine. Information related to stillbirth, low birth weight, and small for gestational age infants is limited. Long-term follow-up is recommended for all infants exposed to antiretroviral medications; children who develop significant organ system abnormalities of unknown etiology (particularly of the CNS or heart) should be evaluated for potential mitochondrial dysfunction. Cases of lactic acidosis and hepatic steatosis related to mitochondrial toxicity have been reported with use of nucleoside reverse transcriptase inhibitors (NRTIs). These adverse events are similar to other rare but life-threatening syndromes that occur during pregnancy (eg, HELLP syndrome). In general, NRTIs are well tolerated and the benefits of use generally outweigh potential risk.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The Health and Human Services (HHS) Perinatal HIV Guidelines consider lamivudine in combination with either abacavir or tenofovir disoproxil fumarate to be a preferred NRTI backbone for initial therapy in antiretroviral-naive pregnant females. The lamivudine/abacavir backbone is not recommended with atazanavir/ritonavir or efavirenz if pretreatment HIV RNA is &gt;100,000 copies/mL. The guidelines consider lamivudine with zidovudine to be an alternative NRTI backbone for initial therapy in antiretroviral-naive pregnant females. The guidelines also consider lamivudine plus tenofovir disoproxil fumarate a recommended dual NRTI backbone in regimens for HIV/HBV-coinfected pregnant females. Use caution with hepatitis B coinfection; hepatitis B flare may occur if lamivudine is discontinued. The pharmacokinetics of lamivudine during pregnancy are not significantly altered, and dosage adjustment is not required.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, ART is recommended for all pregnant females with HIV to keep the viral load below the limit of detection and reduce the risk of perinatal transmission. When HIV is diagnosed during pregnancy in a female who has never received antiretroviral therapy, ART should begin as soon as possible after diagnosis. Females who become pregnant on a stable ART regimen may continue that regimen if viral suppression is effective, appropriate drug exposure can be achieved, contraindications for use in pregnancy are not present, and the regimen is well tolerated. Monitoring during pregnancy is more frequent than in nonpregnant adults; ART should be continued postpartum for all females living with HIV.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In hepatitis B-infected women (not coinfected with HIV), the AASLD chronic hepatitis B treatment guidelines suggest antiviral therapy to reduce the risk of perinatal transmission of hepatitis B in HBsAg-positive pregnant women with an HBV DNA &gt;200,000 units/mL. There are limited data on the level of HBV DNA for when antiviral therapy is routinely recommended (&gt;200,000 units/mL is a conservative recommendation); however, the AASLD recommends against antiviral therapy to reduce the risk of perinatal transmission in HBsAg-positive pregnant women with an HBV DNA &le;200,000 units/mL. Lamivudine is one of the antivirals that has been studied in pregnant women, with most studies initiating antiviral therapy at 28 to 32 weeks gestation and discontinuing antiviral therapy between birth to 3 months postpartum (monitor for ALT flares every 3 months for 6 months following discontinuation). There is insufficient long-term safety data in infants born to mothers who took antiviral agents during pregnancy (AASLD [Terrault 2016]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Health care providers are encouraged to enroll pregnant females exposed to antiretroviral medications as early in pregnancy as possible in the Antiretroviral Pregnancy Registry (1-800-258-4263 or http://www.APRegistry.com). Health care providers caring for HIV-infected females and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (HHS [perinatal] 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186621\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lamivudine is present in breast milk and can be detected in the serum of breastfeeding infants.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Maternal or infant antiretroviral therapy does not completely eliminate the risk of postnatal HIV transmission. In addition, multiclass-resistant virus has been detected in breastfeeding infants despite maternal therapy. Therefore, in the US, where formula is accessible, affordable, safe, and sustainable, and the risk of infant mortality due to diarrhea and respiratory infections is low, females with HIV infection should completely avoid breastfeeding to decrease the potential transmission of HIV (HHS [perinatal] 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">In breastfeeding women with hepatitis B infection (not coinfected with HIV), the AASLD chronic hepatitis B treatment guidelines do not consider antiviral therapy a contraindication to breastfeeding; antivirals are minimally excreted in breast milk and unlikely to cause significant toxicity. However, the unknown risk of low-level exposure to the infant should be discussed with mothers as well as the insufficient long-term safety data in infants born to mothers who took antiviral agents while breastfeeding (AASLD [Terrault 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186622\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some products may contain sucrose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186608\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Manufacturer&rsquo;s labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>All patients:</i> Hepatic function, signs/symptoms of lactic acidosis; signs/symptoms of pancreatitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>HIV patients: </i>Coinfection with HBV (prior to therapy); HIV viral load and CD4 count; immune reconstitution syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hepatitis B patients:</i> Coinfection with HIV (prior to therapy); following discontinuation, monitor hepatic function closely with both clinical and laboratory follow/up for signs/symptoms of HBV relapse/exacerbation (continue for at least several months after stopping treatment)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alternate recommendations:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Chronic Hepatitis B</i>: HBV DNA and ALT (HBV DNA usually done every 3 months until undetectable and then every 3 to 6 months thereafter); HBeAg; anti-HBe (in patients who are HBeAg-positive to monitor for seroconversion); HBsAg; during therapy, consider monitoring amylase (if symptoms of pancreatitis) and lactic acid levels (if clinical concern); following discontinuation, monitor for recurrent viremia, ALT flares, seroreversion, and clinical decompensation every 3 months for at least 1 year (AASLD [Terrault 2016]). As antivirals do not eliminate the risk of hepatocellular carcinoma, continued monitoring for this complication is recommended in at-risk patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186598\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Lamivudine is a cytosine analog. In vitro, lamivudine is triphosphorylated, the principle mode of action is inhibition of HIV reverse transcription via viral DNA chain termination; inhibits RNA- and DNA-dependent DNA polymerase activities of reverse transcriptase. In hepatitis B, the monophosphate form of lamivudine is incorporated into the viral DNA by hepatitis B virus polymerase, resulting in DNA chain termination.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186615\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rapid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Into extravascular spaces</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children (n=38): CSF concentrations were 14.2% &plusmn; 7.9% of the serum concentration</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">V<sub>d</sub>: 1.3 &plusmn; 0.4 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Plasma: &lt;36%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Minor; only known metabolite is trans-sulfoxide metabolite</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Absolute; Cp<sub>max</sub> decreased with food although AUC not significantly affected</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children: Oral solution: 66% &plusmn; 26%; relative bioavailability is 40% lower than with tablets</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents and Adults: Oral solution: 87% &plusmn; 13%; Tablet 150 mg: 86% &plusmn; 16%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intracellular: 10 to 15 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 4 months to 14 years: 2 &plusmn; 0.6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 5 to 7 hours; increased with renal impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric patients 0.5 to 17 years: Median: 1.5 hours (range: 0.5 to 4 hours) (Lewis 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents 13 to 17 years: 0.5 to 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Fed: 3.2 hours; Fasted: 0.9 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Primarily urine (majority as unchanged drug); weight-corrected oral clearance is highest at age 2 years, then declines from age 2 to 12 years, where values then remain comparable to adult values</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186619\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Epivir HBV Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL (240 mL): $234.14</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Epivir Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (240 mL): $133.04</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (LamiVUDine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (240 mL): $119.70</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Epivir HBV Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (60): $1,170.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Epivir Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (60): $498.89</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (30): $498.89</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (LamiVUDine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (60): $966.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (60): $429.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (30): $429.66</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186623\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>3TC (AE, AR, AU, BH, BM, BS, BZ, CR, DO, GT, GY, HK, HN, ID, JM, KR, KW, MX, NI, NZ, PA, QA, SR, SV, TT, UY, ZW);</li>\n      <li>3TC-HBV (ID);</li>\n      <li>Cytivir (BD);</li>\n      <li>Epivir (AE, AT, BB, BE, BH, BR, CY, CZ, DE, DK, EE, EG, ES, FI, FR, GB, GR, HN, HR, HU, IE, IL, IQ, IR, IS, IT, JO, KW, LB, LT, LU, LV, LY, MT, NL, NO, OM, PE, PL, PT, PY, QA, RO, RU, SA, SE, SG, SI, SK, SY, TH, TR, UA, VE, VN, YE);</li>\n      <li>Epivir 3TC (CL);</li>\n      <li>Glamivir (VN);</li>\n      <li>Heplav (ID);</li>\n      <li>Heptavir (ET, LK, UA);</li>\n      <li>Heptodin (CN);</li>\n      <li>Inhavir (CO);</li>\n      <li>Koide (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Ladiwin (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Lamid (BD);</li>\n      <li>Lamidac (IN);</li>\n      <li>Lamidin (BD);</li>\n      <li>Lamidine (TW);</li>\n      <li>Lamiffix (KR);</li>\n      <li>Lamivir (LB, PE, TH);</li>\n      <li>Tabivir (QA);</li>\n      <li>Tizacure (HK);</li>\n      <li>Vuclodir (PY);</li>\n      <li>Zeffiks (UA);</li>\n      <li>Zeffix (AE, AT, AU, BD, BE, BG, BH, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, HR, HU, IE, IL, IT, JO, KR, KW, LB, LT, LU, LV, MT, MY, NL, NO, NZ, PH, PK, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, TH, TR, TW, VN);</li>\n      <li>Zeraffic (HK, KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    3TC (lamivudine) [product monograph]. Laval, Quebec, Canada: ViiV Healthcare ULC; May 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed, Philadelphia, PA: American College of Physicians, 2007, 161.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), US Department of Health and Human Services (HHS). Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV&mdash;United States, 2016. <a href=\"https://stacks.cdc.gov/view/cdc/38856\" target=\"_blank\">https://stacks.cdc.gov/view/cdc/38856</a>. Published April 18, 2016. Accessed July 11, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dienstag JL, Perrillo, RP, Schiff, ER, et al, &ldquo;A Preliminary Trial of Lamivudine for Chronic Hepatitis B Infection,&rdquo; <i>N Engl J Med</i>, 1995, 333(25):1657-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamivudine-drug-information/abstract-text/7477217/pubmed\" target=\"_blank\" id=\"7477217\">7477217</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Epivir (lamivudine) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Epivir HBV (lamivudine) [prescribing information]. Research Triangle Park, NC; GlaxoSmithKline; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eron JJ, Benoit SL, Jemsek J, et al, &ldquo;Treatment With Lamivudine, Zidovudine, or Both in HIV-Positive Patients With 200 to 500 CD4<sup>+</sup> Cells Per Cubic Millimeter,&rdquo; <i>N Engl J Med</i>, 1995, 333(25):1662-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamivudine-drug-information/abstract-text/7477218/pubmed\" target=\"_blank\" id=\"7477218\">7477218</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heptovir (lamivudine) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, Department of Health and Human Services. Updated October 17, 2017. Available at <a href=\"http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf\" target=\"_blank\">http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hilts AE and Fish DN, &ldquo;Dosage Adjustment of Antiretroviral Agents in Patients With Organ Dysfunction,&rdquo; <i>Am J Health Syst Pharm</i>, 1998, 55:2528-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamivudine-drug-information/abstract-text/9853641/pubmed\" target=\"_blank\" id=\"9853641\">9853641</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamivudine-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johnson MA, Verpooten GA, Daniel MJ, et al, &ldquo;Single Dose Pharmacokinetics of Lamivudine in Subjects With Impaired Renal Function and the Effect of Haemodialysis,&rdquo; <i>Br J Clin Pharmacol</i>, 1998, 46(1):21-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamivudine-drug-information/abstract-text/9690945/pubmed\" target=\"_blank\" id=\"9690945\">9690945</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lai CL, Chien RN, Leung NW, et al, &ldquo;A One-Year Trial of Lamivudine for Chronic Hepatitis B,&rdquo; <i>N Engl J Med</i>, 1998, 339(2):61-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamivudine-drug-information/abstract-text/9654535/pubmed\" target=\"_blank\" id=\"9654535\">9654535</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lewis LL, Mueller B, Schock R, et al, &ldquo;A Phase I/II Study to Evaluate the Safety, Toxicity, and Preliminary Efficacy of Combinations of Lamivudine (3TC), Zidovudine (AZT) and Didanosine (ddI) in Children With HIV Infection,&rdquo; <i>Natl Conf Hum Retroviruses Relat Infect (2nd)</i>, 1995, Jan 29-Feb 2:103.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lewis LL, Venzon D, Church J, et al, &ldquo;Lamivudine in Children With Human Immunodeficiency Virus Infection: A Phase I/II Study,&rdquo; <i>J Infect Dis</i>, 1996, 174(1):16-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamivudine-drug-information/abstract-text/8655986/pubmed\" target=\"_blank\" id=\"8655986\">8655986</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucas GM, Ross MJ, Stock PG, et al. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(9): e96-e138.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamivudine-drug-information/abstract-text/25234519/pubmed\" target=\"_blank\" id=\"25234519\">25234519</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Panlilio AL, Cardo DM, Grohskopf LA, et al, &ldquo;Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HIV and Recommendations for Postexposure Prophylaxis,&rdquo; <i>MMWR Recomm Rep</i>, 2005, 54(RR-9):1-17. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5409a1.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5409a1.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamivudine-drug-information/abstract-text/16195697/pubmed\" target=\"_blank\" id=\"16195697\">16195697</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perry CM and Faulds D, &ldquo;Lamivudine. A Review of Its Antiviral Activity, Pharmacokinetic Properties and Therapeutic Efficacy in the Management of HIV Infection,&rdquo; <i>Drugs</i>, 1997, 53(4):657-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamivudine-drug-information/abstract-text/9098665/pubmed\" target=\"_blank\" id=\"9098665\">9098665</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH; American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. <i>Hepatology</i>. 2016;63(1):261-283. doi: 10.1002/hep.28156.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamivudine-drug-information/abstract-text/26566064/pubmed\" target=\"_blank\" id=\"26566064\">26566064</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tremoulet AH, Capparelli EV, Patel P, et al, &ldquo;Population Pharmacokinetics of Lamivudine in Human Immunodeficiency Virus-Exposed and -Infected Infants,&rdquo; <i>Antimicrob Agents Chemother</i>, 2007, 51(12):4297-302.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamivudine-drug-information/abstract-text/17893155/pubmed\" target=\"_blank\" id=\"17893155\">17893155</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services Panel on Treatment of Pregnant Women With HIV Infection and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs in pregnant women with HIV infection and interventions to reduce perinatal HIV transmission in the United States. <a href=\"https://aidsinfo.nih.gov/guidelines/html/3/perinatal/0\" target=\"_blank\">https://aidsinfo.nih.gov/guidelines/html/3/perinatal/0</a>. Updated November 14, 2017. Accessed December 21, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamivudine-drug-information/abstract-text/17555487/pubmed\" target=\"_blank\" id=\"17555487\">17555487</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9544 Version 187.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709005\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F186636\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F186637\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F186676\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F186641\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F186659\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F186642\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F186643\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F16160258\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F186610\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F186595\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F46041979\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F186613\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F186611\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25726720\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F186683\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F186602\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F186616\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F186599\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299572\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F186604\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F186632\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F186620\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F186621\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F186622\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F186608\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F186598\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F186615\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F186619\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F186623\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9544|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=lamivudine-patient-drug-information\" class=\"drug drug_patient\">Lamivudine: Patient drug information</a></li><li><a href=\"topic.htm?path=lamivudine-pediatric-drug-information\" class=\"drug drug_pediatric\">Lamivudine: Pediatric drug information</a></li></ul></div></div>","javascript":null}